53 Participants Needed

VS-6766 + Cetuximab for Colorectal Cancer

AS
Overseen ByArdaman S. Shergill, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new drug combination (VS-6766 and cetuximab) for patients with advanced colorectal cancer who have not responded to other treatments. The combination aims to stop cancer cells from growing and make it easier for the body to fight the cancer. Cetuximab has been used in various combinations for treating advanced colorectal cancer.

Do I need to stop taking my current medications to join the trial?

The trial protocol does not specify if you must stop all current medications, but you cannot take strong CYP3A4 inhibitors or inducers. If you are on these, you must stop them 14 days before starting the trial. Also, avoid grapefruit, grapefruit juice, and St. John's Wort during the trial.

What safety data is available for the treatment of VS-6766 and Cetuximab in colorectal cancer?

The safety data for Cetuximab (Erbitux) in colorectal cancer includes findings from various studies. A Japanese post-marketing surveillance study confirmed the safety of Cetuximab in practical use for metastatic colorectal cancer. Common side effects reported include acneiform rash and paronychia. In a study evaluating Cetuximab and irinotecan as third-line therapy, skin toxicity, diarrhea, nausea, vomiting, and fatigue were observed, with grade 3 toxicity being rare. The severity of skin toxicity was correlated with response and survival rates. Overall, Cetuximab has been shown to be effective with manageable toxicity in heavily pretreated patients.12345

Is the drug Cetuximab a promising treatment for colorectal cancer?

Yes, Cetuximab is a promising drug for treating colorectal cancer. It has been shown to improve survival rates and response in patients with certain types of colorectal cancer, especially when combined with other treatments. It works by targeting specific cancer cell receptors, helping the immune system attack the cancer more effectively.14678

What data supports the idea that VS-6766 + Cetuximab for Colorectal Cancer is an effective drug?

The available research shows that Cetuximab, when combined with other drugs like irinotecan, has been effective in treating advanced colorectal cancer. For example, in one study, patients who had already tried other treatments showed a 20% response rate and lived longer after receiving Cetuximab with irinotecan. Another study found that adding Cetuximab to a treatment plan improved survival and response rates compared to using other drugs alone. Although these studies don't specifically mention VS-6766, they suggest that Cetuximab can be an effective part of a treatment plan for colorectal cancer.14579

Who Is on the Research Team?

Ardaman Shergill, MD - UChicago Medicine

Ardaman Shergill, MD

Principal Investigator

University of Chicago Comprehensive Cancer Center

Are You a Good Fit for This Trial?

Adults with advanced colorectal cancer that has worsened after standard treatments or those who can't tolerate them. Participants must have specific KRAS mutations, not be pregnant or breastfeeding, agree to use contraception, and have no recent major surgeries or other cancer treatments. They should also not be on conflicting medications and must meet health criteria including organ function tests.

Inclusion Criteria

You must have a detectable tumor that can be measured using specific medical criteria.
I am not taking any other experimental drugs.
My colorectal cancer has spread, cannot be cured, and has a KRAS mutation.
See 13 more

Exclusion Criteria

I don't have specific eye conditions like retinal detachment or macular degeneration.
You have had allergic reactions to drugs or biological substances similar to cetuximab, or have a history of red meat allergy or tick bites.
I do not have any severe illnesses that are not under control.
See 25 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1 Dose-Finding

Participants receive VS-6766 and cetuximab in 28-day cycles to determine the maximum tolerated dose

12 cycles (approximately 12 months)
Bi-weekly visits for cetuximab administration

Phase 2 Efficacy

Participants receive the best tolerated dose of VS-6766 and cetuximab to assess efficacy

Up to 12 months
Regular visits for monitoring and pill diary checks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • Cetuximab
  • VS-6766
Trial Overview The trial is testing the safety of combining VS-6766, a new drug, with cetuximab in patients with advanced colorectal cancer. It aims to see how well these drugs work together for up to 24 months of participation. Patients will keep a pill diary as part of the study.
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Group I: Phase 2 (Efficacy Arm/ Expansion Cohort)Experimental Treatment3 Interventions
Group II: Phase 1(Dose-Finding Arm): Group 4 - Lower Dose Level 2Experimental Treatment2 Interventions
Group III: Phase 1(Dose-Finding Arm): Group 3 - Lower Dose Level 1Experimental Treatment2 Interventions
Group IV: Phase 1(Dose-Finding Arm): Group 2- Dose Level 2 (Second Highest Dose)Experimental Treatment2 Interventions
Group V: Phase 1(Dose-Finding Arm): Group 1 - Dose Level 1 (Starting Dose)Experimental Treatment2 Interventions

Cetuximab is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Erbitux for:
🇪🇺
Approved in European Union as Erbitux for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials
1,086
Recruited
844,000+

Verastem, Inc.

Industry Sponsor

Trials
42
Recruited
2,800+

Published Research Related to This Trial

In a study involving 65 patients with advanced colorectal cancer who had previously been treated with multiple therapies, the combination of cetuximab and irinotecan showed a response rate of 20% and a median overall survival of 10.4 months, confirming the efficacy of this treatment regimen.
The treatment was associated with low rates of severe toxicity, with only 8% experiencing grade 3 skin toxicity, indicating that cetuximab and irinotecan can be a safe option for heavily pretreated patients.
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.Pfeiffer, P., Nielsen, D., Yilmaz, M., et al.[2018]
In a post-marketing surveillance study involving 2126 patients with metastatic colorectal cancer, cetuximab was found to be well tolerated, with a median treatment duration of 15.3 weeks and a high incidence of adverse reactions at 89.6%.
The most common adverse reactions included skin disorders (83.7%) and infusion reactions (5.7%), primarily occurring during the first administration, indicating that while side effects are common, they align with previous reports and suggest that cetuximab is clinically useful in this patient population.
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer.Ishiguro, M., Watanabe, T., Yamaguchi, K., et al.[2022]
The CIFRA study is investigating the effectiveness of cetuximab combined with irinotecan and fluorouracil in patients with metastatic colorectal cancer who have a specific genetic profile (FcγRIIIa V/V), which may enhance the drug's action through a mechanism called Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).
This phase II trial aims to determine if patients with the FcγRIIIa V/V genotype have a higher response rate to cetuximab, potentially improving treatment outcomes, while also assessing safety and survival metrics.
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.Ottaiano, A., Scala, S., Normanno, N., et al.[2020]

Citations

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. [2018]
A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. [2022]
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. [2020]
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. [2021]
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis. [2019]
[The efficacy of cetuximab for metastatic colorectal cancer]. [2018]
Cetuximab. [2020]
Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. [2022]
Cetuximab: appraisal of a novel drug against colorectal cancer. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security